

Major R&D Pipeline: 3ADCs

As of Apr 2022






	(Phase 1)	Phase 2	Phase 3	Filed	
(US/EU/Asia) HER2+ BC 2L~/1L DESTINY-Breast07	(JP/US) NSCLC, TNBC, HR+ BC, SCLC, urothelial, GC, esophageal TROPION-PanTumor01	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia)HER2+ BC 3L DESTINY-Breast02	(JP/US/EU/Asia) HER2+ BC 2L DESTINY-Breast03	
(US/EU/Asia) HER2 low BC chemo naïve/ post chemo DESTINY-Breast08	(JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembrolizumab combo) TROPION-Lung02	(China) HER2+ GC 3L DESTINY-Gastric06	(JP/US/EU/Asia) HER2 low BC post chemo DESTINY-Breast04	(EU) HER2+ GC 2L DESTINY-Gastric02	
(JP/US/EU/Asia) HER2+ GC combo, 2L~/1L DESTINY-Gastric03	(JP/US/EU) NSCLC (w/o actionable mutation, durvalumab combo) TROPION-Lung04	(JP/US/EU)HER2+/mutated NSCLC 2L~ DESTINY-Lung01	(JP/US/EU/Asia) HER2+ BC post neoadjuvant DESTINY-Breast05	(US) HER2 mutated NSCLC 2L~ DESTINY-Lung01	
(EU/Asia)HER2+ NSCLC (durvalumab combo) 1L DESTINY-Lung03	(US/EU/Asia) TNBC (durvalumab combo) BEGONIA	(JP/US/EU/Asia) HER2 mutated NSCLC 2L~ DESTINY-Lung02	(JP/US/EU/Asia) HER2 low BC chemo naïve DESTINY-Breast06		
(US/EU) BC, bladder (nivolumab combo)	(JP/US/EU/Asia) solid tumors (AZD5305 combo) PETRA	(CN) HER2 mutated NSCLC 2L~ DESTINY-Lung05	(JP/US/EU/Asia)HER2+ BC 1L DESTINY-Breast09		
(US/EU) BC, NSCLC (pembrolizumab combo)	(JP/US/EU/Asia) NSCLC	(US/EU/Asia) NSCLC (durvalumab combo) 2L~ HUDSON	(JP/US/EU/Asia) HER2+ BC neoadjuvant DESTINY-Breast11		
(US/EU/Asia) solid tumors (AZD5305 combo) PETRA	(JP/US)EGFR mutated NSCLC (osimertinib combo)	(JP/US/EU) HER2+ CRC 3L DESTINY-CRC01	(JP/EU/Asia) HER2+ GC 2L DESTINY-Gastric04		
	(JP/US) HER3+ BC	(JP/US/EU/Asia) HER2+ CRC 3L DESTINY-CRC02	(JP/US/EU/Asia) NSCLC 1L (w/ exon 19 or exon 20 mutation) DESTINY-Lung04		
		(JP/US/EU/Asia) HER2 mutated tumor DESTINY-PanTumor01	(JP/US/EU/Asia) NSCLC 2/3L TROPION-Lung01		
		(US/EU/Asia) HER2 expressing tumor DESTINY-PanTumor02	(JP/US/EU/Asia) HR+ BC 2/3L TROPION-Breast01		
		(JP/US/EU/Asia) NSCLC (w/ actionable mutation) TROPION-Lung05	(JP/US/EU/Asia) NSCLC (w/o actionable mutation, pembro combo) TROPION-Lung08		
		(JP/US/EU/Asia) EGFR mutated NSCLC, HERTHENA-Lung01	(JP/US/EU/Asia) EGFR mutated NSCLC, HERTHENA-Lung02		




- ENHERTU®
- Dato-DXd
- HER3-DXd




BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer
 : project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
 : Breakthrough Designation (US)

Major R&D Pipeline: Alpha

As of Apr 2022

Phase 1	Phase 2	Phase 3	Filed
DS-7300 (JP/US) B7-H3-directed ADC ESCC, CRPC, squamous NSCLC, etc.	PLX2853 (US) BET inhibitor AML	Valemetostat (DS-3201) (JP/US/EU/Asia) EZH1/2 inhibitor PTCL  	Valemetostat (DS-3201) (JP) EZH1/2 inhibitor ATL/L 
DS-6000 (US) CDH6-directed ADC Renal cell carcinoma, ovarian cancer	PLX2853 (US) BET inhibitor Solid tumor	Valemetostat (DS-3201) (EU) EZH1/2 inhibitor BCL	VN-0107/MEDI3250 (JP) Live attenuated influenza vaccine nasal spray
DS-1055 (JP/US) Anti-GARP antibody Solid tumors	PLX2853 (US) BET inhibitor Gynecologic neoplasms, ovarian cancer	DS-1001 (JP) Mutant IDH1 inhibitor Glioma	Minnebro (JP) MR blocker Diabetic nephropathy
DS-1211 (US)  TNAP inhibitor Pseudoxanthoma elasticum	PLX2853 (US) BET inhibitor Prostate cancer	DS-7300 (JP/US/EU/Asia) B7-H3-directed ADC SCLC	VN-0102/JVC-001 (JP) Measles mumps rubella combined vaccine
DS-6016 (JP) Anti-ALK2 antibody Fibrodysplasia ossificans progressiva	DS-1594 (US) Menin-MLL binding inhibitor AML, ALL	DS-5141 (JP)  ENA oligonucleotide DMD	DS-5670 (JP) SARS-CoV-2 mRNA vaccine COVID-19 (booster vaccination)
DS-7011 (US) Anti-TLR7 antibody Systemic lupus erythematosus	VN-0200 (JP) RS virus vaccine RS virus infection	DS-5670 (JP) SARS-CoV-2 mRNA vaccine COVID-19 (initial vaccination)	

-  Oncology
-  Specialty medicine
-  Vaccine

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma, FOP: Fibrodysplasia ossificans progressive, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, SCLC: small cell lung cancer, PTCL: peripheral T-cell lymphoma
: project in oncology that is planned to be submitted for approval based on the results of phase 2 trials  SAKIGAKE Designation (JP)  Orphan drug designation (JP/US/Europe)